Maintaining Investments in New Innovation Act
This bill appears to be dead.
No action has been recorded in 1 year, 2 months. The structural status shown below reflects an earlier milestone, not current activity.
Summary · Congressional Research Service (nonpartisan)
This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Who introduced this
Donald Davis
DemocratU.S. Representative · NC-1
Bipartisan — 41 cosponsors (5 D, 36 R)
Ask AI About This Bill
Get plain-language answers with direct quotes from the bill text.
Your Representatives
Enter your address to see how your representatives voted on this bill.
Your address is only used to find your district and is never saved. See how it works
Votes
Public Opinion
No votes yet — be the first to weigh in.
to cast your vote
Your voice matters — let representatives know where you stand.
Comments
No comments yet. to be the first to weigh in.